Anthropic wants to make its own drugs with help from Claude.
Rohan Paul Twitter · Rohan Paul (@rohanpaul_ai) · 2026-07-04
Anthropic is launching Claude Science, a drug discovery initiative targeting neglected diseases and rare genetic disorders, backed by the acquisition of Coefficient Bio, the hiring of AlphaFold researcher John Jumper, and Novartis CEO Vas Narasimhan joining its board.
Appears in
Extraction
Topics: ai-drug-discoveryanthropicclaude-sciencebiotechneglected-diseases
Claims
- Anthropic's Claude Science initiative aims to apply AI to laboratory research in the same transformative way Claude Code applied AI to programming.
- Anthropic's initial drug programs will focus on neglected diseases including rare genetic disorders and tropical conditions, which have clearer biology but weaker commercial incentives.
- Anthropic acquired Coefficient Bio and hired AlphaFold researcher John Jumper, signaling a serious long-term commitment to biology.
- Novartis CEO Vas Narasimhan joined Anthropic's board to provide direct pharma-level input on product decisions.
- Anthropic is deliberately targeting overlooked disease programs to avoid competing with its existing pharmaceutical customers.
Key quotes
Claude Science is meant to do for lab research what Claude Code did for programming.
Anthropic also avoids competing with pharma customers by choosing overlooked programs.
Anthropic bought Coefficient Bio and hired AlphaFold researcher John Jumper, so this is not a side experiment.